查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2092986

數位認知風險評估市場預測至2034年：按解決方案類型、技術、應用、最終用戶和地區分類的全球分析

Digital Cognitive Risk Assessment Market Forecasts to 2034 - Global Analysis By Solution Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球數位認知風險評估市場規模將達到 13 億美元，並在預測期內以 28.5% 的複合年成長率成長，到 2034 年將達到 96 億美元。

數位認知風險評估是指利用技術驅動的評估系統，旨在透過自動化篩檢和預測分析，識別、量化和監測個體認知能力下降、神經退化性疾病以及腦部相關健康併發症。這些解決方案整合了人工智慧、數位生物標記、遠端監測功能和標準化的認知功能測試方案，以便在臨床症狀出現之前檢測到認知能力下降的早期徵兆。該技術包括基於軟體的篩檢平台、臨床決策支援工具、人群健康分析系統以及與穿戴式裝置整合的監測解決方案，使醫療保健專業人員、保險公司和研究人員能夠進行風險分層並實施有針對性的預防干預措施。

轉向預防醫學

全球向預防性醫療模式的轉變顯著提升了對數位化認知風險評估解決方案的需求，這類方案能夠及早識別失智症及相關疾病，從而在造成不可逆神經損傷之前進行干預。健康保險公司意識到，與晚期失智症治療相比，早期療育能夠顯著降低成本。製藥公司需要風險分層工具來篩選合適的臨床試驗參與者。認知篩檢正日益成為政府老化計畫中的標準預防性醫療服務。這些系統性變革正在創造多元化的收入來源，並為臨床、研究和保險公司等各個領域帶來市場穩定性。

融入臨床工作流程

如何將數位化認知風險評估工具整合到現有臨床工作流程中，同時不給醫護人員造成過重的時間負擔，是阻礙其廣泛應用的一大挑戰。基層醫療醫生必須在有限的就診時間內同時處理多項請求，而且可能缺乏正確解讀數位化風險評分的培訓。與電子健康記錄的整合需要耗資巨資進行技術開發和持續維護。這些操作上的障礙限制了數位化醫療的市場滲透，使其僅限於能夠投入專項資源實施數位化醫療的專科神經科診所和研究機構。

擴大保險報銷範圍

認知功能篩檢作為預防性服務，日益受到認可並納入保險範圍，這為數位化認知風險評估服務提供者帶來了龐大的商機。聯邦醫療保險（Medicare）和私人保險公司正在擴大年度健康檢查的保險覆蓋範圍，將認知功能評估納入其中。基於價值的醫療保健合約正在激勵對包括失智症在內的慢性疾病進行早期發現和管理。與責任醫療組織（ACO）的獎勵正在為認知功能篩檢在人群中的普及創造機會。這些保險報銷趨勢正在將認知風險評估從一項可選的附加服務轉變為標準診療流程，從而顯著擴大目標市場規模。

診斷假陽性

認知風險評估中假陽性的風險威脅市場對數位篩檢工具的信心，可能導致患者不必要的焦慮，並造成額外的檢查和醫療成本的增加。訓練資料中包含的演算法偏差可能導致對低估人群的風險預測不準確。隨著市場擴張，監管機構對基於軟體的診斷工具的健康益處聲明的審查也在加強。這些品質和問責方面的擔憂引起了保守的臨床醫生和規避風險的醫療保健系統的抵制，儘管技術能力強大，但這些工具的普及速度仍然緩慢。

新型冠狀病毒（COVID-19）的影響：

新冠疫情擾亂了常規的面對面認知篩檢，同時也加速了遠端數位風險評估平台的開發和部署。醫療服務提供者需要非接觸式替代方案來維持預防性照護的連續性。疫情後，結合遠距數位評估和有針對性的面對面追蹤的混合篩檢模式已成為標準做法。這次危機也產生了關於新冠病毒對認知功能影響的重要數據，從而改進了風險模型，並意識提升。對遠端保健基礎設施的持續投入有助於維持遠距評估能力。

在預測期內，數位認知功能篩檢平台細分市場預計將佔據最大的市場佔有率。

由於其廣泛的普及性和與基層醫療及社區健康保健機構的成熟整合，預計在預測期內，數位認知篩檢平台將佔據最大的市場佔有率。這些平台透過平板電腦、智慧型手機和網頁介面提供簡潔、標準化的認知評估，且只需極少的員工培訓。與傳統的神經心理學評估相比，醫療系統非常重視數位篩檢的高效率和成本效益。社區健康促進計畫正在利用這些工具來識別大規模失智症風險。自動化評分和報告的擴充性使得在整個醫療網路中進行系統性部署成為可能。

在預測期內，人工智慧（AI）領域預計將呈現最高的複合年成長率。

在預測期內，人工智慧（AI）領域預計將呈現最高的成長率，這主要得益於其能夠分析複雜的多模態數據，並識別傳統篩檢方法無法檢測到的認知風險的細微徵兆。基於不同資料集訓練的機器學習模型能夠提高早期神經退化性疾病的診斷準確率。自然語言處理技術能夠分析作為認知衰退指標的語音模式。這些人工智慧功能顯著提高了篩檢的敏感度和特異性，並降低了在較簡單的數字評估中普遍存在的假陽性率問題。法律規範也越來越接受基於人工智慧的診斷軟體。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其先進的醫療保健數據基礎設施以及在聯邦醫療保險（Medicare）年度健康檢查中完善的認知功能篩檢保險報銷機制。美國之所以處於主導地位，是因為其在阿茲海默症研究方面投入了大量資金，擁有領先的學術聯盟來產生大規模的認知功能資料集，並且美國食品藥物管理局（FDA）為基於軟體的醫療設備提供了有利的監管途徑。健康保險公司正在積極尋求具有成本效益的早期檢測工具，以控制與失智症相關的支出。創業投資正在支持數位認知功能評估技術的持續創新。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於中國、日本和韓國人口快速老化，對失智症預防基礎設施的迫切需求。政府的數位健康舉措正在推動公立醫院網路採用新技術。中產階級健康意識的提高正在推動消費者對認知功能篩檢的需求。該地區的技術生態系統正在以具有競爭力的價格開發專有平台。新興市場健康保險的擴展正在增加患者獲得以往無法獲得的預防性認知功能評估服務的機會。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、企業發展和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球數位認知風險評估市場：依解決方案類型分類

  • 數位認知篩檢平台
  • 基於人工智慧的風險評估軟體
  • 臨床決策支援系統
  • 數位生物標記平台
  • 遠端認知監測解決方案
  • 人口風險評估平台

第6章：全球數位認知風險評估市場：依技術分類

  • 人工智慧
  • 機器學習
  • 預測分析
  • 巨量資料分析
  • 雲端運算
  • 數位生物標記
  • 醫療物聯網（IoMT）

第7章 全球數位認知風險評估市場：依應用領域分類

  • 失智症風險評估
  • 阿茲海默症篩檢
  • 中風風險評估
  • 神經退化性疾病篩檢
  • 認知障礙的偵測
  • 臨床試驗參與者的篩檢
  • 團體健康風險管理

第8章：全球數位認知風險評估市場：以最終用戶分類

  • 醫院
  • 診斷中心
  • 神經科診所
  • 研究機構
  • 製藥公司
  • 醫療保健支付方
  • 其他最終用戶

第9章 全球數字認知風險評估市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第10章 戰略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第11章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第12章：公司簡介

  • Cambridge Cognition Holdings plc
  • Cogstate Ltd.
  • CNS Vital Signs
  • Creyos Corporation
  • Philips Healthcare
  • GE HealthCare
  • Siemens Healthineers AG
  • Canon Medical Systems Corporation
  • FUJIFILM Healthcare
  • Tempus AI
  • Verily Life Sciences
  • Oracle Health
  • IBM Corporation
  • Natus Medical Incorporated
  • Compumedics Limited
  • EMOTIV Inc.
  • BrainCo Inc.
Product Code: SMRC38155

According to Stratistics MRC, the Global Digital Cognitive Risk Assessment Market is accounted for $1.3 billion in 2026 and is expected to reach $9.6 billion by 2034 growing at a CAGR of 28.5% during the forecast period. Digital cognitive risk assessment refers to technology-enabled evaluation systems designed to identify, quantify, and monitor individual susceptibility to cognitive decline, neurodegenerative disease, and brain-related health complications through automated screening and predictive analytics. These solutions integrate artificial intelligence, digital biomarkers, remote monitoring capabilities, and standardized cognitive testing protocols to detect early signs of impairment before clinical symptoms become apparent. The technology encompasses software-based screening platforms, clinical decision support tools, population health analytics systems, and wearable-integrated monitoring solutions that enable healthcare providers, payers, and researchers to stratify risk and implement targeted preventive interventions.

Market Dynamics:

Driver:

Preventive healthcare shift

The global transformation toward preventive healthcare models is driving substantial demand for digital cognitive risk assessment solutions that enable early identification of dementia and related conditions before irreversible neurological damage occurs. Healthcare payers recognize the cost-saving potential of early intervention compared to late-stage dementia care. Pharmaceutical companies require risk stratification tools to identify appropriate clinical trial participants. Government aging strategies increasingly incorporate cognitive health screening as standard preventive care. These systemic shifts create multiple revenue streams and market stability across clinical, research, and payer segments.

Restraint:

Clinical workflow integration

The challenge of integrating digital cognitive risk assessment tools into existing clinical workflows without adding a significant time burden to healthcare providers limits widespread adoption. Primary care physicians face competing demands during brief patient encounters and may lack training to interpret digital risk scores appropriately. Electronic health record integration requires costly technical development and ongoing maintenance. These operational barriers concentrate market penetration among specialized neurology practices and research institutions with dedicated resources for digital health implementation.

Opportunity:

Insurance reimbursement expansion

The expanding recognition of cognitive screening as a reimbursable preventive service presents significant commercial opportunities for digital cognitive risk assessment providers. Medicare and private insurers increasingly cover annual wellness visits that incorporate cognitive assessment. Value-based care contracts incentivize early identification and management of chronic conditions, including dementia. Partnerships with accountable care organizations create population-level deployment opportunities. These reimbursement trends transform cognitive risk assessment from an optional add-on to a standard care protocol, dramatically expanding the addressable market size.

Threat:

Diagnostic false positives

The risk of false positive cognitive risk assessments generating unnecessary patient anxiety, follow-up testing, and healthcare costs threatens market confidence in digital screening tools. Algorithmic bias in training data may produce inaccurate risk predictions for underrepresented demographic groups. Regulatory scrutiny of health claims for software-based diagnostic tools intensifies as the market expands. These quality and liability concerns create resistance among conservative clinicians and risk-averse healthcare systems, slowing mainstream adoption despite technological capabilities.

Covid-19 Impact:

The COVID-19 pandemic disrupted routine in-person cognitive screening while accelerating the development and deployment of remote digital risk assessment platforms. Healthcare providers required contactless alternatives to maintain preventive care continuity. Post-pandemic, hybrid screening models combining digital remote assessment with targeted in-person follow-up have become standard practice. The crisis also generated significant data on COVID-related cognitive impacts, improving risk models, and increasing public awareness of cognitive health monitoring. Sustained telehealth infrastructure investment supports continued remote assessment capabilities.

The digital cognitive screening platforms segment is expected to be the largest during the forecast period

The digital cognitive screening platforms segment is expected to account for the largest market share during the forecast period, due to their broad accessibility and established integration into primary care and community health settings. These platforms deliver brief, standardized cognitive assessments through tablets, smartphones, and web interfaces that require minimal staff training. Healthcare systems value the efficiency and cost-effectiveness of digital screening compared to traditional neuropsychological evaluation. Population health programs leverage these tools for large-scale dementia risk identification. The scalability of automated scoring and reporting supports enterprise deployment across health networks.

The artificial intelligence segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the artificial intelligence segment is predicted to witness the highest growth rate, driven by its capacity to analyze complex multi-modal data and identify subtle cognitive risk signatures invisible to traditional screening methods. Machine learning models trained on diverse datasets improve detection accuracy for early-stage neurodegenerative conditions. Natural language processing enables analysis of speech patterns for cognitive decline indicators. These AI capabilities significantly enhance screening sensitivity and specificity, reducing false positive rates that plague simpler digital assessments. Regulatory frameworks increasingly accommodate AI-based diagnostic software.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to advanced healthcare data infrastructure and established reimbursement for cognitive screening within Medicare annual wellness visits. The United States leads with substantial Alzheimer's research funding, major academic consortia generating large cognitive datasets, and favorable FDA regulatory pathways for software-based medical devices. Healthcare payers actively seek cost-effective early identification tools to manage dementia-related expenditures. Venture capital investment supports continuous innovation in digital cognitive assessment technologies.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly aging populations in China, Japan, and South Korea, creating urgent demand for dementia prevention infrastructure. Government digital health initiatives support technology adoption across public hospital networks. Growing middle-class health awareness drives consumer demand for cognitive health screening. The region's technology ecosystem enables indigenous platform development at competitive price points. Health insurance expansion in emerging markets increases patient access to preventive cognitive assessment services previously unavailable.

Key players in the market

Some of the key players in Digital Cognitive Risk Assessment Market include Cambridge Cognition Holdings plc, Cogstate Ltd., CNS Vital Signs, Creyos Corporation, Philips Healthcare, GE HealthCare, Siemens Healthineers AG, Canon Medical Systems Corporation, FUJIFILM Healthcare, Tempus AI, Verily Life Sciences, Oracle Health, IBM Corporation, Natus Medical Incorporated, Compumedics Limited, EMOTIV Inc. and BrainCo Inc..

Key Developments:

In June 2026, Cambridge Cognition Holdings plc launched a next-generation digital cognitive risk assessment platform featuring AI-driven pattern recognition that identifies subtle preclinical markers of dementia from brief smartphone-based cognitive tests.

In May 2026, Cogstate Ltd. expanded its digital cognitive screening portfolio to include population health analytics capabilities, enabling healthcare systems to identify geographic clusters of elevated dementia risk for targeted intervention deployment.

In April 2026, Creyos Corporation introduced a cloud-based cognitive risk assessment system designed for primary care integration that delivers immediate risk scores and automated referral recommendations based on standardized digital cognitive testing.

Solution Types Covered:

  • Digital Cognitive Screening Platforms
  • AI-Based Risk Assessment Software
  • Clinical Decision Support Systems
  • Digital Biomarker Platforms
  • Remote Cognitive Monitoring Solutions
  • Population Risk Assessment Platforms

Technologies Covered:

  • Artificial Intelligence
  • Machine Learning
  • Predictive Analytics
  • Big Data Analytics
  • Cloud Computing
  • Digital Biomarkers
  • Internet of Medical Things (IoMT)

Applications Covered:

  • Dementia Risk Assessment
  • Alzheimers Disease Screening
  • Stroke Risk Evaluation
  • Neurodegenerative Disease Screening
  • Cognitive Impairment Detection
  • Clinical Trial Participant Screening
  • Population Health Risk Management

End Users Covered:

  • Hospitals
  • Diagnostic Centers
  • Neurology Clinics
  • Research Institutes
  • Pharmaceutical Companies
  • Healthcare Payers
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Digital Cognitive Risk Assessment Market, By Solution Type

  • 5.1 Digital Cognitive Screening Platforms
  • 5.2 AI-Based Risk Assessment Software
  • 5.3 Clinical Decision Support Systems
  • 5.4 Digital Biomarker Platforms
  • 5.5 Remote Cognitive Monitoring Solutions
  • 5.6 Population Risk Assessment Platforms

6 Global Digital Cognitive Risk Assessment Market, By Technology

  • 6.1 Artificial Intelligence
  • 6.2 Machine Learning
  • 6.3 Predictive Analytics
  • 6.4 Big Data Analytics
  • 6.5 Cloud Computing
  • 6.6 Digital Biomarkers
  • 6.7 Internet of Medical Things (IoMT)

7 Global Digital Cognitive Risk Assessment Market, By Application

  • 7.1 Dementia Risk Assessment
  • 7.2 Alzheimer's Disease Screening
  • 7.3 Stroke Risk Evaluation
  • 7.4 Neurodegenerative Disease Screening
  • 7.5 Cognitive Impairment Detection
  • 7.6 Clinical Trial Participant Screening
  • 7.7 Population Health Risk Management

8 Global Digital Cognitive Risk Assessment Market, By End User

  • 8.1 Hospitals
  • 8.2 Diagnostic Centers
  • 8.3 Neurology Clinics
  • 8.4 Research Institutes
  • 8.5 Pharmaceutical Companies
  • 8.6 Healthcare Payers
  • 8.7 Other End Users

9 Global Digital Cognitive Risk Assessment Market, By Geography

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 United Kingdom
    • 9.2.2 Germany
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Netherlands
    • 9.2.7 Belgium
    • 9.2.8 Sweden
    • 9.2.9 Switzerland
    • 9.2.10 Poland
    • 9.2.11 Rest of Europe
  • 9.3 Asia Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 South Korea
    • 9.3.5 Australia
    • 9.3.6 Indonesia
    • 9.3.7 Thailand
    • 9.3.8 Malaysia
    • 9.3.9 Singapore
    • 9.3.10 Vietnam
    • 9.3.11 Rest of Asia Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Colombia
    • 9.4.4 Chile
    • 9.4.5 Peru
    • 9.4.6 Rest of South America
  • 9.5 Rest of the World (RoW)
    • 9.5.1 Middle East
      • 9.5.1.1 Saudi Arabia
      • 9.5.1.2 United Arab Emirates
      • 9.5.1.3 Qatar
      • 9.5.1.4 Israel
      • 9.5.1.5 Rest of Middle East
    • 9.5.2 Africa
      • 9.5.2.1 South Africa
      • 9.5.2.2 Egypt
      • 9.5.2.3 Morocco
      • 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

  • 10.1 Industry Value Network and Supply Chain Assessment
  • 10.2 White-Space and Opportunity Mapping
  • 10.3 Product Evolution and Market Life Cycle Analysis
  • 10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

  • 11.1 Mergers and Acquisitions
  • 11.2 Partnerships, Alliances, and Joint Ventures
  • 11.3 New Product Launches and Certifications
  • 11.4 Capacity Expansion and Investments
  • 11.5 Other Strategic Initiatives

12 Company Profiles

  • 12.1 Cambridge Cognition Holdings plc
  • 12.2 Cogstate Ltd.
  • 12.3 CNS Vital Signs
  • 12.4 Creyos Corporation
  • 12.5 Philips Healthcare
  • 12.6 GE HealthCare
  • 12.7 Siemens Healthineers AG
  • 12.8 Canon Medical Systems Corporation
  • 12.9 FUJIFILM Healthcare
  • 12.10 Tempus AI
  • 12.11 Verily Life Sciences
  • 12.12 Oracle Health
  • 12.13 IBM Corporation
  • 12.14 Natus Medical Incorporated
  • 12.15 Compumedics Limited
  • 12.16 EMOTIV Inc.
  • 12.17 BrainCo Inc.

List of Tables

  • Table 1 Global Digital Cognitive Risk Assessment Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Digital Cognitive Risk Assessment Market Outlook, By Solution Type (2023-2034) ($MN)
  • Table 3 Global Digital Cognitive Risk Assessment Market Outlook, By Digital Cognitive Screening Platforms (2023-2034) ($MN)
  • Table 4 Global Digital Cognitive Risk Assessment Market Outlook, By AI-Based Risk Assessment Software (2023-2034) ($MN)
  • Table 5 Global Digital Cognitive Risk Assessment Market Outlook, By Clinical Decision Support Systems (2023-2034) ($MN)
  • Table 6 Global Digital Cognitive Risk Assessment Market Outlook, By Digital Biomarker Platforms (2023-2034) ($MN)
  • Table 7 Global Digital Cognitive Risk Assessment Market Outlook, By Remote Cognitive Monitoring Solutions (2023-2034) ($MN)
  • Table 8 Global Digital Cognitive Risk Assessment Market Outlook, By Population Risk Assessment Platforms (2023-2034) ($MN)
  • Table 9 Global Digital Cognitive Risk Assessment Market Outlook, By Technology (2023-2034) ($MN)
  • Table 10 Global Digital Cognitive Risk Assessment Market Outlook, By Artificial Intelligence (2023-2034) ($MN)
  • Table 11 Global Digital Cognitive Risk Assessment Market Outlook, By Machine Learning (2023-2034) ($MN)
  • Table 12 Global Digital Cognitive Risk Assessment Market Outlook, By Predictive Analytics (2023-2034) ($MN)
  • Table 13 Global Digital Cognitive Risk Assessment Market Outlook, By Big Data Analytics (2023-2034) ($MN)
  • Table 14 Global Digital Cognitive Risk Assessment Market Outlook, By Cloud Computing (2023-2034) ($MN)
  • Table 15 Global Digital Cognitive Risk Assessment Market Outlook, By Digital Biomarkers (2023-2034) ($MN)
  • Table 16 Global Digital Cognitive Risk Assessment Market Outlook, By Internet of Medical Things (IoMT) (2023-2034) ($MN)
  • Table 17 Global Digital Cognitive Risk Assessment Market Outlook, By Application (2023-2034) ($MN)
  • Table 18 Global Digital Cognitive Risk Assessment Market Outlook, By Dementia Risk Assessment (2023-2034) ($MN)
  • Table 19 Global Digital Cognitive Risk Assessment Market Outlook, By Alzheimer's Disease Screening (2023-2034) ($MN)
  • Table 20 Global Digital Cognitive Risk Assessment Market Outlook, By Stroke Risk Evaluation (2023-2034) ($MN)
  • Table 21 Global Digital Cognitive Risk Assessment Market Outlook, By Neurodegenerative Disease Screening (2023-2034) ($MN)
  • Table 22 Global Digital Cognitive Risk Assessment Market Outlook, By Cognitive Impairment Detection (2023-2034) ($MN)
  • Table 23 Global Digital Cognitive Risk Assessment Market Outlook, By Clinical Trial Participant Screening (2023-2034) ($MN)
  • Table 24 Global Digital Cognitive Risk Assessment Market Outlook, By Population Health Risk Management (2023-2034) ($MN)
  • Table 25 Global Digital Cognitive Risk Assessment Market Outlook, By End User (2023-2034) ($MN)
  • Table 26 Global Digital Cognitive Risk Assessment Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 27 Global Digital Cognitive Risk Assessment Market Outlook, By Diagnostic Centers (2023-2034) ($MN)
  • Table 28 Global Digital Cognitive Risk Assessment Market Outlook, By Neurology Clinics (2023-2034) ($MN)
  • Table 29 Global Digital Cognitive Risk Assessment Market Outlook, By Research Institutes (2023-2034) ($MN)
  • Table 30 Global Digital Cognitive Risk Assessment Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 31 Global Digital Cognitive Risk Assessment Market Outlook, By Healthcare Payers (2023-2034) ($MN)
  • Table 32 Global Digital Cognitive Risk Assessment Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.